The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Chip-based human liver–intestine and liver–skin co-cultures – A first step toward systemic repeated dose substance testing in vitro
Open accessAbstract
Systemic repeated dose safety assessment and systemic efficacy evaluation of substances are currently carried out on laboratory animals and in humans due to the lack of predictive alternatives. Relevant international regulations, such as OECD and ICH guidelines, demand long-term testing and oral, dermal, inhalation, and systemic exposure routes for such evaluations. So-called “human-on-a-chip” concepts are aiming to replace respective animals and humans in substance evaluation with miniaturized functional human organisms. The major technical hurdle toward success in this field is the life-like combination of human barrier organ models, such as intestine, lung or skin, with parenchymal organ equivalents, such as liver, at the smallest biologically acceptable scale. Here, we report on a reproducible homeostatic long-term co-culture of human liver equivalents with either a reconstructed human intestinal barrier model or a human skin biopsy applying a microphysiological system. We used a multi-organ chip (MOC) platform, which provides pulsatile fluid flow within physiological ranges at low media-to-tissue ratios. The MOC supports submerse cultivation of an intact intestinal barrier model and an air–liquid interface for the skin model during their co-culture with the liver equivalents respectively at 1/100.000 the scale of their human counterparts in vivo. To increase the degree of organismal emulation, microfluidic channels of the liver–skin co-culture could be successfully covered with human endothelial cells, thus mimicking human vasculature, for the first time. Finally, exposure routes emulating oral and systemic administration in humans have been qualified by applying a repeated dose administration of a model substance – troglitazone – to the chip-based co-cultures.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Engineering of functional, perfusable 3D microvascular networks on a chip
Kim, S., Lee, H., Chung, M., & Jeon, N. L. (2013) · Lab on a Chip · doi:10.1039/c3lc41320a · Cited by 872
Wagner, I., Materne, E.-M., Brincker, S., Süßbier, U., Frädrich, C., Busek, M., Sonntag, F., Sakharov, D. A., Trushkin, E. V., Tonevitsky, A. G., et al. (2013) · Lab on a Chip · doi:10.1039/c3lc50234a · Cited by 476
Self-citationZhang, C., Zhao, Z., Abdul Rahim, N. A., van Noort, D., & Yu, H. (2009) · Lab on a Chip · doi:10.1039/b915147h · Cited by 340
Imura, Y., Sato, K., & Yoshimura, E. (2010) · Analytical Chemistry · doi:10.1021/ac100806x · Cited by 172
Fabre, K. M., Livingston, C., & Tagle, D. A. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214538916 · Cited by 82
Research works printed but not linked: 34
- U. Marx, H. Walles, S. Hoffmann, G. Lindner, R. Horland, F. Sonntag, et al., Human-on-a-chip Developments: A Translational Cutting-edge Alternative to Systemic Safety Assessment and Efficiency Evaluation of Substances in Laboratory Animals and Man, ATLA, vol. 40, 2012, pp. 235–57. <http://www.ncbi.nlm.nih.gov/pubmed/23215661>. · DOI · Paper page
- Huh, 2012, Microengineered physiological biomimicry: organs-on-chips, Lab Chip., 12, 2156, 10.1039/c2lc40089h · DOI · Paper page
- Esch, 2014, How multi-organ microdevices can help foster drug development☆, Adv. Drug Deliv. Rev., 69–70, 158, 10.1016/j.addr.2013.12.003 · DOI
- Wikswo, 2014, The relevance and potential roles of microphysiological systems in biology and medicine, Exp. Biol. Med. (Maywood), 239, 1061, 10.1177/1535370214542068 · DOI · Paper page
- Materne, 2013, Chip-based liver equivalents for toxicity testing–organotypicalness versus cost-efficient high throughput, Lab Chip., 13, 3481, 10.1039/c3lc50240f · DOI
- Hwan, 2009, A micro cell culture analog (microCCA) with 3-D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs, Lab Chip., 9, 1385, 10.1039/b901377f · DOI · Paper page
- Sung, 2010, A microfluidic device for a pharmacokinetic–pharmacodynamic (PK–PD) model on a chip, Lab Chip., 10, 446, 10.1039/b917763a · DOI · Paper page
- Bricks, 2014, Development of a new microfluidic platform integrating co-cultures of intestinal and liver cell lines, Toxicol. In Vitro., 28, 885, 10.1016/j.tiv.2014.02.005 · DOI
- Mertsching, 2009, Generation and transplantation of an autologous vascularized bioartificial human tissue, Transplantation, 88, 203, 10.1097/TP.0b013e3181ac15e1 · DOI
- Schanz, 2010, Vascularised human tissue models: a new approach for the refinement of biomedical research, J. Biotechnol., 148, 56, 10.1016/j.jbiotec.2010.03.015 · DOI
- Scheller, 2013, Upcyte microvascular endothelial cells repopulate decellularized scaffold, Tissue Eng. Part C Methods, 19, 57, 10.1089/ten.tec.2011.0723 · DOI
- Yeon, 2012, In vitro formation and characterization of a perfusable three-dimensional tubular capillary network in microfluidic devices, Lab Chip., 12, 2815, 10.1039/c2lc40131b · DOI · Paper page
- Lee, 2014, A bioengineered array of 3D microvessels for vascular permeability assay, Microvasc. Res., 91, 90, 10.1016/j.mvr.2013.12.001 · DOI
- Schimek, 2013, Integrating biological vasculature into a multi-organ-chip microsystem, Lab Chip., 13, 3588, 10.1039/c3lc50217a · DOI · Paper page
- Wu, 2008, Development of perfusion-based micro 3-D cell culture platform and its application for high throughput drug testing, Sensors Actuat. B Chem., 129, 231, 10.1016/j.snb.2007.07.145 · DOI
- Powers, 2002, A microfabricated array bioreactor for perfused 3D liver culture, Biotechnol. Bioeng., 78, 257, 10.1002/bit.10143 · DOI · Paper page
- Thielicke, 2014, PIVlab – towards user-friendly, affordable and accurate digital particle image velocimetry in MATLAB, J. Open Res. Softw., 2, e30, 10.5334/jors.bl · DOI · Paper page
- Gupta, 2013, Permeation of insulin, calcitonin and exenatide across Caco-2 monolayers: measurement using a rapid, 3-day system, PLoS ONE, 8, e57136, 10.1371/journal.pone.0057136 · DOI
- Artursson, 1993, Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments, Pharm. Res., 10, 1123, 10.1023/A:1018903931777 · DOI · Paper page
- Le Ferrec, 2001, In Vitro models of the intestinal barrier, ATLA, 29, 649
- Gripon, 2002, Infection of a human hepatoma cell line by hepatitis B virus, Proc. Natl. Acad. Sci. USA, 99, 15655, 10.1073/pnas.232137699 · DOI · Paper page
- Yu, 2012, In vitro 3D human small intestinal villous model for drug permeability determination, Biotechnol. Bioeng., 109, 2173, 10.1002/bit.24518 · DOI · Paper page
- Sung, 2011, Microscale 3-D hydrogel scaffold for biomimetic gastrointestinal (GI) tract model, Lab Chip., 11, 389, 10.1039/C0LC00273A · DOI · Paper page
- Loi, 1999, Clinical pharmacokinetics of troglitazone, Clin. Pharmacokinet., 37, 91, 10.2165/00003088-199937020-00001 · DOI
- Rogue, 2011, Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes, PLoS ONE, 6, e18816, 10.1371/journal.pone.0018816 · DOI
- Limonciel, 2011, Lactate is an ideal non-invasive marker for evaluating temporal alterations in cell stress and toxicity in repeat dose testing regimes, Toxicol. In Vitro., 25, 1855, 10.1016/j.tiv.2011.05.018 · DOI
- H. Yamazaki, A. Shibata, M. Suzuki, M. Nakajima, N. Shimada, F.P. Guengerich, et al., Oxidation of Troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes abstract, vol. 27, 1999, pp. 1260–1266. · DOI · Paper page
- Izumi, 1997, Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from In Vitro Data, J. Pharmacol. Exp. Ther., 280, 1392, 10.1016/S0022-3565(24)36525-5 · DOI
- H.E. Cubitt, J.B. Houston, A. Galetin, Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data (2011) 864–873. http://dx.doi.org/10.1124/dmd.110.036566. · DOI
- Yasushi Yoshigae, 2000, Characterization of UDP-glucuronosyltransferases(UGTS) involved in the metabolism of troglitazone in rats and humans, J. Toxicol. Sci., 25, 433, 10.2131/jts.25.5_433 · doi:10.2131/jts.25.5_433
- Funk, 2001, Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity. In Vivo and in Vitro interaction at the canalicular bile salt export pump (BSEP) in the Rat, Mol. Pharmacol., 59, 627, 10.1016/S0026-895X(24)12255-9 · DOI · Paper page
- Kaimal, 2009, Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones, J. Pharmacol. Exp. Ther., 330, 125, 10.1124/jpet.109.151233 · DOI
- Rogue et al., 2011. Comparative gene expression profiles induced by PPARγ and PPARαγ agonists in human hepatocytes.pdf, (n.d.). · doi:10.1016/j.toxlet.2011.05.947
- Corpe, 2001, Effects of type-2 diabetes and troglitazone on the expression patterns of small intestinal sugar transporters and PPAR-Gamma in the zucker diabetic fatty Rat, Digestion, 63, 116, 10.1159/000051879 · DOI
Cited by
Human organs-on-chips for disease modelling, drug development and personalized medicine
Ingber, D. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00466-9 · Cited by 1,589
Maschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., Ramme, A. P., Hübner, J., Lindner, M., Drewell, C., Bauer, S., Thomas, A., et al. (2015) · Lab on a Chip · doi:10.1039/c5lc00392j · Cited by 861
Self-citationZhang, Y. S., Aleman, J., Shin, S. R., Kilic, T., Kim, D., Mousavi Shaegh, S. A., Massa, S., Riahi, R., Chae, S., Hu, N., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612906114 · Cited by 833
Organ-on-a-chip: recent breakthroughs and future prospects
Wu, Q., Liu, J., Wang, X., Feng, L., Wu, J., Zhu, X., Wen, W., & Gong, X. (2020) · BioMedical Engineering OnLine · doi:10.1186/s12938-020-0752-0 · Cited by 701
Organs-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development
Ronaldson-Bouchard, K., & Vunjak-Novakovic, G. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.02.011 · Cited by 657
Metadata
- Authors
- Maschmeyer, I., Hasenberg, T., Jaenicke, A., Lindner, M., Lorenz, A. K., Zech, J., Garbe, L.-A., Sonntag, F., Hayden, P., Ayehunie, S., Lauster, R., Marx, U., & Materne, E.-M.
- Venue
- European Journal of Pharmaceutics and Biopharmaceutics
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 95
- Issue
- Pt A
- Pages
- 77-87
- ISSN
- 0939-6411 (ISSN-L)
- OpenAlex
- W1981403460
- Cited by
- 218
- References
- 5
- FWCI
- 11.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 408 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Defense Advanced Research Projects Agency (W911NF-12-2-0039)
- National Institutes of Health (R43GM108164)
- Bundesministerium für Bildung und Forschung (0315569)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chip-based human liver–intestine and liver–skin co-cultures – A first step toward systemic repeated dose substance testing in vitro. https://app.cochat.ai/papers/10.1016/j.ejpb.2015.03.002
- The paper
- Maschmeyer, I., Hasenberg, T., Jaenicke, A., Lindner, M., Lorenz, A. K., Zech, J., Garbe, L.-A., Sonntag, F., Hayden, P., Ayehunie, S., Lauster, R., Marx, U., & Materne, E.-M. (2015). Chip-based human liver–intestine and liver–skin co-cultures – A first step toward systemic repeated dose substance testing in vitro. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2015.03.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.